Alnylam Pharmaceuticals, Inc. $ALNY Stock Holdings Trimmed by Baillie Gifford & Co.

Key Points

• Baillie Gifford trimmed its position in Alnylam by 6.8% in Q4, selling 188,377 shares and now holds 2,600,979 shares (about 1.97% of the company) valued at roughly $1.034 billion; institutional investors own 92.97% of the stock.
• Alnylam missed Q4 estimates with EPS of $1.25 vs. $1.43 and revenue of $1.10B vs. $1.16B, though revenue was up 84.9% year‑over‑year; the stock trades near $322 with a $43.0B market cap and a consensus rating of "Moderate Buy" (average target $473.87).
• Company insiders have sold 40,946 shares valued at about $13.22M over the last 90 days (including sales by the CEO and EVP), leaving insiders with 1.20% ownership.

Baillie Gifford & Co. lowered its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) by 6.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,600,979 shares of the biopharmaceutical company's stock after selling 188,377 shares during the period. Alnylam Pharmaceuticals makes up 0.9% of Baillie Gifford & Co.'s holdings, making the stock its 24th largest position. Baillie Gifford & Co. owned approximately 1.97% of Alnylam Pharmaceuticals worth $1,034,279,000 as of its most recent SEC filing.

Several other hedge funds have also recently added to or reduced their stakes in the business. OFI Invest Asset Management increased its position in shares of Alnylam Pharmaceuticals by 5.8% during the 3rd quarter. OFI Invest Asset Management now owns 403 shares of the biopharmaceutical company's stock valued at $184,000 after purchasing an additional 22 shares during the period. Howard Capital Management Inc. increased its position in shares of Alnylam Pharmaceuticals by 2.9% during the 3rd quarter. Howard Capital Management Inc. now owns 854 shares of the biopharmaceutical company's stock valued at $389,000 after purchasing an additional 24 shares during the period. Frank Rimerman Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 2.0% during the 3rd quarter. Frank Rimerman Advisors LLC now owns 1,251 shares of the biopharmaceutical company's stock valued at $570,000 after purchasing an additional 24 shares during the period. Coastal Bridge Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 2.3% during the 3rd quarter. Coastal Bridge Advisors LLC now owns 1,097 shares of the biopharmaceutical company's stock valued at $500,000 after purchasing an additional 25 shares during the period. Finally, Meridian Financial Advisors LLC increased its position in shares of Alnylam Pharmaceuticals by 3.5% during the 3rd quarter. Meridian Financial Advisors LLC now owns 828 shares of the biopharmaceutical company's stock valued at $378,000 after purchasing an additional 28 shares during the period. Institutional investors own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Performance

Shares of ALNY stock opened at $322.38 on Monday. Alnylam Pharmaceuticals, Inc. has a 1-year low of $220.54 and a 1-year high of $495.55. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. The company has a market capitalization of $43.01 billion, a price-to-earnings ratio of 188.52 and a beta of 0.39. The stock's fifty day simple moving average is $324.17 and its 200-day simple moving average is $390.16.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its quarterly earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing analysts' consensus estimates of $1.43 by ($0.18). Alnylam Pharmaceuticals had a net margin of 6.43% and a return on equity of 69.02%. The business had revenue of $1.10 billion for the quarter, compared to analysts' expectations of $1.16 billion. During the same quarter in the prior year, the firm posted ($0.65) EPS. The business's quarterly revenue was up 84.9% compared to the same quarter last year. On average, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, CEO Yvonne Greenstreet sold 6,958 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 13th. The stock was sold at an average price of $310.08, for a total transaction of $2,157,536.64. Following the transaction, the chief executive officer owned 85,662 shares in the company, valued at approximately $26,562,072.96. The trade was a 7.51% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, January 13th. The shares were sold at an average price of $370.33, for a total value of $848,055.70. Following the transaction, the executive vice president owned 21,264 shares in the company, valued at $7,874,697.12. This represents a 9.72% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 40,946 shares of company stock valued at $13,218,751 in the last ninety days. Company insiders own 1.20% of the company's stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on ALNY. Truist Financial lowered their price target on Alnylam Pharmaceuticals from $535.00 to $530.00 and set a "buy" rating on the stock in a research report on Thursday, January 8th. Canaccord Genuity Group lifted their price target on Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a "buy" rating in a research report on Tuesday, February 17th. Oppenheimer began coverage on Alnylam Pharmaceuticals in a research report on Wednesday, January 7th. They set an "outperform" rating and a $500.00 price target on the stock. Wells Fargo & Company lowered their price target on Alnylam Pharmaceuticals from $479.00 to $376.00 and set an "equal weight" rating on the stock in a research report on Tuesday, January 20th. Finally, Bank of America reiterated a "buy" rating on shares of Alnylam Pharmaceuticals in a research report on Thursday, February 12th. One equities research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average target price of $473.87.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.